Physicians' Academy for Cardiovascular Education

CV Inflammation

Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.

Need for a stratified approach to improve treatment of IHD

3' education - May 24, 2022 - Prof. Filippo Crea, MD

The journey from hypothesis to reality on inflammation in CVD

10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD

IL-6 as therapeutic target in inflammation and CVD

10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD

Inflammation and anti-inflammatory therapy in CVD

10' education - Apr. 11, 2022 - Prof. Thomas Lüscher, MD

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD

Immunity and inflammation in atherosclerosis - no longer just a theory

10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Panel discussion: Measuring inflammation in the coronary circulation

15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD

Detecting residual cardiovascular risk using coronary CT angiography

10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD

Novel modulators of inflammation in atherosclerosis

10' education - Oct. 6, 2021 - Prof. Peter Libby, MD

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

Strong evidence for colchicine in patients with chronic coronary disease

5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD

Lp(a) and immune metabolism

5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

CRP levels associated with risk of cancer in stable CVD

5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

Challenges in targeting residual risk in diabetic patients, post ACS

10' education - Sep. 25, 2019 - Prof. Peter Libby, MD

Understanding and managing obesity-related HFpEF

10' education - July 22, 2019 - Milton Packer, MD

Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation

3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway

3' education - Nov. 11, 2018

The predictive role of biomarkers in CV risk assessment

10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA

What is the situation one year after the presentation about the CANTOS trial?

10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Also as CME accredited e-learning

The CANTOS trial: Implications for the management of patients with residual risk

10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME

Relationships of CRP and C-peptide with CV events and all-cause mortality in new onset T2DM

News - Sep. 21, 2022

EASD 2022 In patients with new onset T2DM in the DD2 cohort, high CRP was a better marker of all-cause mortality than future CV events, whereas high C-peptide was a better marker of increased CV risk.

E-learning Inflammation: The next therapeutic frontier in targeting cardiovascular risk

Accredited e-Learning

Online-CME - This course consists of 4 parts.
This course consists of 4 parts.

"There are 3 patients with residual inflammatory risk for every 1 patients with residual cholesterol risk," says prof. Ridker. Learn how perspectives on inflammation in atherosclerosis have changed from 1970s up until now and how (novel) anti-inflammatory therapies may reduce CVD risk.

Need for a stratified approach to improve treatment of IHD

3' education - May 24, 2022 - Prof. Filippo Crea, MD
We need a better understanding of the mechanisms leading to ischemic heart disease (IHD) to improve treatment, says prof. Crea. He explains 4 mechanisms that can lead to thrombus formation and IHD.

EAS 2022 We need a better understanding of the mechanisms leading to ischemic heart disease (IHD) to improve treatment, says prof. Crea. He explains 4 mechanisms that can lead to thrombus formation and IHD.

Elevated sLOX-1 levels in ACS patients predict fatal events at 1 year

Literature - May 11, 2022 - Kraler S, et al. - Eur Heart J. 2022

Elevated plasma sLOX-1 levels –observed during acute coronary syndromes (ACS) – predict fatal events beyond both established CV risk factors and the updated GRACE score, in the multicenter SPUM-ACS study.

The journey from hypothesis to reality on inflammation in CVD

10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD
On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality.

On the topic of inflammation in CVD, prof. Libby and Ridker discuss the journey from theory to testing the hypothesis to reality. "Ultimately, the inflammation hypothesis is going to yield great dividends for our patients", concluded prof. Libby.

IL-6 as therapeutic target in inflammation and CVD

10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD

"There are 3 patients with residual inflammatory risk for every 1 patients with residual cholesterol risk," says prof. Ridker. What are current and future therapies to lower inflammation in these patients with residual inflammatory risk?

Inflammation and anti-inflammatory therapy in CVD

10' education - Apr. 11, 2022 - Prof. Thomas Lüscher, MD
What is the role of inflammation in the occlusion of coronary arteries? Prof. Lüscher presents findings from studies on this topic and discusses outcomes of trials with anti-inflammatory therapies.

What is the role of inflammation in the occlusion of coronary arteries? Prof. Lüscher presents findings from studies on this topic and discusses outcomes of trials with anti-inflammatory therapies.

3 Challenges when targeting inflammation in residual CV risk

10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD
Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Prof. Crea discusses three challenges when considering anti-inflammatory therapies for patients with residual CV risk.

Immunity and inflammation in atherosclerosis - no longer just a theory

10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD
Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

Prof. Libby introduces a series of presentations on immunity and inflammation in atherosclerosis. He discusses perspectives on atherosclerosis from 1976 up until now.

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19. patiënten met COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

Highly-purified EPA does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Panel discussion: Measuring inflammation in the coronary circulation

15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD
Peter Libby, John Deanfield and Charalambos Antoniades talk about the relevance of coronary inflammation in clinical practice and discuss how inflammation in the coronary circulation can be measured.

Peter Libby, John Deanfield and Charalambos Antoniades talk about the relevance of coronary inflammation in clinical practice and discuss how inflammation in the coronary circulation can be measured.